Loading…
HIND
Vyome Holdings, Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 92943X104
$2.21-0.23%Price as of Aug 29, 18:48 UTC · updated once a day, after the close
Key metrics
- Market cap
- $15.48M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.61
- ROE
- -999.17%
- Profit margin
- 0.00%
- Revenue growth
- -46.00%
- Beta
- —
- 52-week high
- $9.56
- 52-week low
- $1.75
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.00▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 10 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $3.44 | $446.00 | $1,450.00 | $39,092.00 | $475,600.00 | $1,305,000.00 | $1,653,000.00 | $18,009,000.00 | $57,507,000.00 | $76,995,000.00 | |
| P/S | 9.9x | 75.5x | 6.3x | 0.7x | 1.6x | 2.2x | 4.0x | 13.6x | 15.8x | 34.8x | 136.2x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AEONAEON Biopharma, Inc. | $0.31 | — | — | — | — | $15.67M |
| LSTALisata Therapeutics Inc | $1.69 | — | 1.9x | — | -101.66% | $15.23M |
| NRSNNeuroSense Therapeutics Ltd. | $0.42 | — | — | — | -2174.98% | $15.88M |
| ADVBAdvanced Biomed Inc. | $9.70 |
About the company
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
- 9
- Cambridge, United States
Company description provided by Yahoo Finance.